Key facts
- This page summarizes Chen Schor's Form 4 filing for Karyopharm Therapeutics Inc. (KPTI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 29 May 2025, 16:07.
Chen Schor - 28 May 2025 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)
- Reporting relationship
- Director
- Issuer ticker
- KPTI
- Reported as of
- 28 May 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 May 2025, 16:07:05 UTC
- Prior SEC filing
- 04 Feb 2025
- Next SEC filing
- 27 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nancy Smith, Attorney-in-Fact for Chen Schor
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chen Schor filed Form 4 for Karyopharm Therapeutics Inc. (KPTI) on 29 May 2025.
Change
- Previous filing in this sequence was filed on 04 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001340875
Primary reporting owner
Schor Chen
- Relationship
- Director
- Address
- C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON
- Signature
- /s/ Nancy Smith, Attorney-in-Fact for Chen Schor
- Signature date
- 29 May 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KPTI
transaction
Derivative
Nonstatutory Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +4,600
- Change %
- Price
- $0.000000
- Shares after
- 4,600
- Date
- 28 May 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,600
- Exercise price
- $4.48
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
Footnote F2
This option vests as to 100% of the underlying shares on May 28, 2026.